Drug news
NICE recommends Ofev (ninedanib) for treatment of idiopathic pulmonary fibrosis - Boehringer
The National Institute of Health and Care Excellence (NICE) has recommended the use of Ofev ( ninedanib) from Boehringer in patients with idiopathic pulmonary fibrosis where the patient has a forced vital capacity of between 50% and 80% predicted and subject to a discount from the manufacturer. Treatment is to be stopped if the disease progresses in any 12 month period.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.